文献速递膀胱癌与上尿路尿路上皮癌

组织学亚型与晚期尿路上皮癌PD-1/PD-L1阻断治疗反应:回顾性研究

Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
PubMed 文献 · J Urol · 2020-01-23

该多中心回顾性研究纳入519例接受免疫检查点抑制剂的晚期尿路上皮癌患者,比较纯尿路上皮癌与变异型尿路上皮癌的疗效。结果显示两组客观缓解率相当(28% vs 29%,p=0.90),总生存无显著差异,但神经内分泌特征患者总生存较差(4.6个月,HR 2.75)。变异型不应排除免疫检查点抑制剂治疗。

要点

  • 变异型与纯尿路上皮癌的ORR相当(28% vs 29%,p=0.90)
  • 神经内分泌特征患者中位OS仅4.6个月(HR 2.75,p=0.003)
  • 变异型组织学不应作为排除免疫检查点抑制剂的依据

核心结论

  • 变异型尿路上皮癌不应排除患者接受免疫检查点抑制剂治疗。
  • 神经内分泌特征肿瘤患者总生存更差,需特别关注。

研究设计与样本

  • 多中心回顾性队列研究,覆盖18家机构。
  • 纳入519例接受免疫检查点抑制剂的晚期尿路上皮癌患者,ORR、OS和PFS分析分别纳入395、406和403例。

主要发现

  • 纯vs变异型尿路上皮癌ORR为28% vs 29%(p=0.90),各亚型与纯型相比无显著差异。
  • 纯型中位OS 11.0个月 vs 变异型10.1个月(p=0.60);神经内分泌特征患者中位OS 4.6个月(9例,HR 2.75,95%CI 1.40-5.40,p=0.003)。
  • 纯型中位PFS 4.1个月 vs 变异型5.2个月(p=0.43);神经内分泌特征中位PFS 3.7个月(HR 1.87,95%CI 0.92-3.79,p=0.09)。

临床怎么用

  • 临床决策中不应因变异型组织学而排除免疫检查点抑制剂。
  • 对含神经内分泌特征的患者应预期总生存较差并加强监测。

局限性

  • 回顾性研究设计。
  • 神经内分泌特征亚组样本量小(9例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Urinary tract cancer can be pure urothelial carcinoma, pure nonurothelial carcinoma or variant urothelial carcinoma (defined here as mixed urothelial carcinoma). Little is known regarding outcomes for patients with variant urothelial carcinoma receiving immune checkpoint inhibitors. We hypothesized that variant urothelial carcinoma does not compromise immune checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma. MATERIALS AND METHODS: We performed a retrospective cohort study across 18 institutions. Demographic, clinicopathological, treatment and outcomes data were collected for patients with advanced urothelial carcinoma who received immune checkpoint inhibitors. Patients were divided into pure vs variant urothelial carcinoma subgroups, with variant urothelial carcinoma further divided by type of variant (ie squamous, neuroendocrine etc). We compared overall response rate using univariate and multivariate logistic regression and progression-free survival and overall survival using Kaplan-Meier and univariate and multivariate Cox proportional hazards. RESULTS: Overall 519 patients were identified, with 395, 406 and 403 included in overall response rate, overall survival and progression-free survival analyses, respectively. Overall response rate to immune checkpoint inhibitors between patients with pure vs variant urothelial carcinoma was comparable (28% vs 29%, p=0.90) without significant differences for individual subtypes vs pure urothelial carcinoma. Median overall survival for patients with pure urothelial carcinoma was 11.0 months vs 10.1 months for variant urothelial carcinoma (p=0.60), but only 4.6 months for patients with neuroendocrine features (9 patients, HR 2.75, 95% CI 1.40-5.40 vs pure urothelial carcinoma, p=0.003). Median progression-free survival was 4.1 months for pure vs 5.2 months for variant urothelial carcinoma (p=0.43) and 3.7 months for neuroendocrine features (HR 1.87, 95% CI 0.92-3.79 vs pure urothelial carcinoma, p=0.09). CONCLUSIONS: Overall response rate to immune checkpoint inhibitors was comparable across histological types. However, overall survival was worse for patients with tumors containing neuroendocrine features. Variant urothelial carcinoma should not exclude patients from receiving immune checkpoint inhibitors.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Miller NJ, Khaki AR, Diamantopoulos LN, et al. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020. PMID: 31971495. doi:10.1097/JU.0000000000000761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。